Biocon Dirección

Dirección controles de criterios 4/4

El CEO de Biocon's es Siddharth Mittal , nombrado en Dec 2019, tiene una permanencia de 4.33 años. compensación anual total es ₹47.88M, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.07% de las acciones de la empresa, por valor de ₹225.27M. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 4.3 años, respectivamente.

Información clave

Siddharth Mittal

Chief Executive Officer (CEO)

₹47.9m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	4.4yrs
Participación del CEO	0.07%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Siddharth Mittal en comparación con los beneficios de Biocon?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹12b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹48m	₹48m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹6b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹42m	₹42m	₹6b
Dec 31 2021	n/a	n/a	₹7b
Sep 30 2021	n/a	n/a	₹7b
Jun 30 2021	n/a	n/a	₹7b
Mar 31 2021	₹43m	₹43m	₹7b
Dec 31 2020	n/a	n/a	₹6b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹7b
Mar 31 2020	₹49m	₹31m	₹8b

Compensación vs. Mercado: La compensación total ($USD574.37K) de Siddharth está en línea con el promedio de empresas de tamaño similar en el mercado Indian ($USD562.53K).

Compensación vs. Ingresos: La compensación de Siddharth ha sido consistente con los resultados de la empresa en el último año.

CEO

Siddharth Mittal (45 yo)

4.4yrs

Permanencia

₹47,880,000

Compensación

Mr. Siddharth Mittal, BCom, CA, CPA has been CEO and Director of Biocon Limited since December 1, 2019. He has been Managing Director of Biocon Limited since April 01, 2020 and served as its Joint Managing...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kiran Mazumdar-Shaw	Founder & Executive Chairperson	45.5yrs	₹30.00m	40.59% ₹ 147.3b
Siddharth Mittal	MD, CEO & Director	4.4yrs	₹47.88m	0.070% ₹ 252.6m
Peter James Bains	Group Chief Executive Officer	less than a year	₹3.28m	sin datos
Arun Gupta	Head of Operations	1.1yrs	sin datos	sin datos
Atanu Roy	Group Chief Information Officer	3.7yrs	sin datos	sin datos
Saurabh Paliwal	Head of Investor Relations	1.8yrs	sin datos	sin datos
Mayank Verma	Company Secretary & Compliance Officer	4.8yrs	₹5.75m	sin datos
Seema Ahuja	Global Head of Communications & Corporate Brand	no data	sin datos	sin datos
Maninder Puri	Head of Human Resources	no data	sin datos	sin datos
Paul Thomas	Chief Commercial Officer	no data	sin datos	sin datos
Abhijit Zutshi	Commercial Head of Biocon Global Generics	no data	sin datos	0.019% ₹ 67.5m
Manoj Pananchukunnath	Head of R&D and Regulatory Sciences	no data	sin datos	0.0074% ₹ 26.8m

2.7yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 532523 se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kiran Mazumdar-Shaw	Founder & Executive Chairperson	45.5yrs	₹30.00m	40.59% ₹ 147.3b
Siddharth Mittal	MD, CEO & Director	4.4yrs	₹47.88m	0.070% ₹ 252.6m
Ravi Mazumdar	Non-Executive Non-Independent Director	23.8yrs	₹5.87m	0.44% ₹ 1.6b
Bobby Parikh	Independent Non-Executive Director	5.8yrs	₹7.43m	sin datos
Naina Lal Kidwai	Additional Non-Executive Independent Director	2.1yrs	₹6.48m	sin datos
Satish Garg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Nicholas Haggar	Independent Director	less than a year	sin datos	sin datos
Shashank Joshi	Member of Scientific Advisory Board	no data	sin datos	sin datos
Rekha Menon	Independent Director	less than a year	sin datos	sin datos
Meleveetil Damodaran	Lead Independent Director	8.1yrs	₹5.99m	sin datos
Eric Mazumdar	Non-Executive Director	2.5yrs	₹5.27m	0.27% ₹ 965.6m
John Petrie	Member of Scientific Advisory Board	no data	sin datos	sin datos

4.4yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 532523 se considera experimentada (4.3 años de antigüedad promedio).

Biocon Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insider recently sold ₹5.3m worth of stock

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Insider recently sold ₹1.8m worth of stock

Recent updates

Investor sentiment improves as stock rises 17%

Insider recently sold ₹5.3m worth of stock

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹2.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹13m worth of stock

Insider recently sold ₹40m worth of stock

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insider recently sold ₹4.2m worth of stock

Biocon Limited Announces Board Changes

Second quarter 2023 earnings released: EPS: ₹0.39 (vs ₹1.16 in 2Q 2022)

Biocon Limited to Report Q2, 2023 Results on Nov 14, 2022

Insider recently sold ₹4.1m worth of stock

Insider recently sold ₹3.8m worth of stock

Price target decreased to ₹379

Biocon Limited Announces Directors Resignation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocon Limited to Report Q3, 2023 Results on Jan 24, 2023

Biocon Limited to Report Q1, 2023 Results on Jul 27, 2022

Biocon Limited (NSEI:BIOCON) agreed to acquire 26% stake in AMPYR Renewable Energy Resources Eleven Private Limited for INR 75 million.

Upcoming dividend of ₹0.50 per share

Now 20% undervalued after recent price drop

Chief Human Resources Officer recently sold ₹1.3m worth of stock

Chief Human Resources Officer recently sold ₹1.8m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹2.2m worth of stock

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Investor sentiment deteriorated over the past week

Insider recently sold ₹1.6m worth of stock

Insider recently sold ₹6.8m worth of stock

Price target increased to ₹399

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biocon Reportedly in Talks with Mylan to Merge Biosimilar Businesses

Insider recently sold ₹4.7m worth of stock

Insufficient new directors

Chief Human Resources Officer recently sold ₹1.8m worth of stock

Chief Human Resources Officer recently sold ₹7.0m worth of stock

Insider recently sold ₹1.0m worth of stock

Second quarter 2022 earnings released: EPS ₹1.16 (vs ₹1.47 in 2Q 2021)

Chief Human Resources Officer recently sold ₹2.6m worth of stock

Chief Human Resources Officer recently sold ₹1.1m worth of stock